A Phase 2 Clinical Study of REC-3964 in Adults for the Reduction of Recurrent Clostridioides Difficile Infection (CDI)
Latest Information Update: 18 Jun 2025
At a glance
- Drugs REC-163964 (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions
- Acronyms ALDER
- Sponsors Recursion Pharmaceuticals
Most Recent Events
- 12 Jun 2025 The timeframe for safety endpoints has been changed to 8 weeks, and a new efficacy endpoint has been added.
- 12 Jun 2025 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: Study terminated due to business decision
- 11 May 2025 Status changed from recruiting to active, no longer recruiting.